Improvement in LFTs with pirfenidone treatment. LFTs: (A) AST, (B) ALT, and (C) ALP were compared between pretreatment levels (24 months prior to starting pirfenidone, shown in red circles) and levels during treatment (0-12 months, shown in blue circles) for all participants. Data for the 10 participants who continued in the extension trial: (D) AST, (E) ALT, and (F) ALP levels. Data are presented as best-fit lines with 95% confidence intervals in gray, analyzed by 2-way analysis of variance. All LFTs showed significant improvement with P < .0001. AST, aspartate transaminase.
Figure 2.

Improvement in LFTs with pirfenidone treatment. LFTs: (A) AST, (B) ALT, and (C) ALP were compared between pretreatment levels (24 months prior to starting pirfenidone, shown in red circles) and levels during treatment (0-12 months, shown in blue circles) for all participants. Data for the 10 participants who continued in the extension trial: (D) AST, (E) ALT, and (F) ALP levels. Data are presented as best-fit lines with 95% confidence intervals in gray, analyzed by 2-way analysis of variance. All LFTs showed significant improvement with P < .0001. AST, aspartate transaminase.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal